Is Vor Biopharma financially healthy?
Yes
Vor Biopharma could pay off all its debt with 0.4 years of earnings.
The numbers behind it
Net debt / EBITDA0.4 years
Cash vs. debt$396M vs. $3M
Current ratio18.2×Short-term assets for each $1 of bills due within a year
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Vor Biopharma
Data as of Nov 13, 2026.